Moderna (MRNA) Tops Q4 EPS by 51c, Beats on Revenue

Moderna (NASDAQ: MRNA) reported Q4 EPS of ($2.11), $0.51 better than the analyst estimate of ($2.62). Revenue for the quarter came in at $678 million versus the consensus estimate of $662.84 million.

For earnings history and earnings-related data on Moderna (MRNA) click here.

You May Also Be Interested In

• KeyBanc Downgrades Primoris Services Corporation (PRIM) to Sector Weight
• Gyre Therapeutics (GYRE) files for 30.22M share offering by selling stockholders
• Hyperscale Data reports Bitcoin treasury of 726.9 BTC worth $45.9M